CoA Therapeutics presents timeline towards PKAN clinical trial

from | March 29, 2022

CoA Therapeutics, a BridgeBio-affiliated company, has completed a Phase I study in healthy volunteers evaluating the safety, tolerability and drug-like properties of BBP-671. We are presenting the healthy volunteer data from the Phase I study at the 4th Pan American Congress on Parkinson's Disease and Movement Disorders, May 26-28, 2022.
In 2022, we are focusing on two activities: improving our formulation for PKAN patients and obtaining feedback on our clinical trial design from regulatory authorities in the EU and the US. Based on your feedback from the survey, we are developing small tablets for use in our clinical trial. We are working with the EMA and later in the year with the FDA to seek their advice on our clinical plans. These activities take time and we hope to open trial centers in the US and Europe in mid-2023.
We know that time is of the essence for people with PKAN and their families, and we are doing our best to move forward as quickly as possible.

Source: 13.03.2022, Communication from CoA-Therapeutics to the PKAN community

Subscribe to our Hoffnungsbaum newsletter!

With our newsletter e-mails you will receive valuable information about NBIA. If you would like to receive additional information on individual NBIA variants or special information for researchers/clinicians in addition to the general newsletter, please click here: Subscribe to additional information

Privacy policy

You have successfully registered!